NCT00005862View on ClinicalTrials.gov

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

July 31, 2004

Conditions
Gastrointestinal Stromal TumorSarcoma
Interventions
DRUG

semaxanib

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005862 - SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas | Biotech Hunter | Biotech Hunter